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Sarah Ng and colleagues first showed that whole-exome 
sequencing  (WES  -  sequencing  of  all  the  exons  in  the 
genome) can be used to identify disease genes in 2009 
[1]. Clearly, WES represents a revolutionary technology. 
In light of the ever increasing number of novel disease 
genes that have been discovered with WES, it has almost 
come to seem routine, and in fact the first descriptions of 
applications of WES to make clinical decisions in the care 
of  patients  have  begun  to  appear  [2].  The  article  by 
Lisenka  Vissers  and  colleagues  in  the  December  2010 
issue of Nature Genetics [3] demonstrates that the revo-
lution is far from over. By providing convincing evidence 
that WES can be used to detect de novo mutations in 
patients  with  sporadic  cases  of  non-syndromic  mental 
retardation, the authors [3] have extended the range of 
clinical situations in which WES can be used and given 
suggestive  evidence  that  de  novo  mutations  are  a 
common cause of mental retardation.
Analysis strategies for disease-gene discovery with 
WES data
One of the main challenges in WES is the sheer number 
of variants that are found in an exome. It is likely that 
each  one  of  us  -  healthy  or  not  -  carries  multiple 
sequence  variants,  such  as  nonsense  mutations,  that 
most geneticists would have assessed as disease-causing 
before  whole-exome  and  whole-genome  sequencing 
showed  us  how  common  such  changes  are  in  human 
genomes. The challenge in molecular genetic diagnostics 
is  thus  quickly  shifting  from  the  identification  of 
sequence variants to the interpretation of the variants: 
which  of  the  tens  to  hundreds  of  rare  variants  in  an 
exome sequence with apparent pathogenic potential is 
the disease-causing mutation?
Initial analysis strategies in exome sequencing sought 
to  identify  genes  with  rare,  potentially  pathogenic 
variants  in  all  or  most  sequenced  individuals  with  a 
given disease [1,4-6]. This approach, which we will call 
inter  section filtering, narrows down the candidate set of 
genes by removing variants also found in databases of 
common  polymorphisms  such  as  dbSNP  and  also 
removing  variants  that  are  deemed  to  be  unlikely  to 
cause  disease,  such  as  synonymous  or  intergenic 
nucleotide  substitu  tions.  Several  studies  used  linkage 
analysis in addition to WES to narrow down the region 
of the exome in which to search for candidate mutations. 
For autosomal reces  sive disorders, it is possible to infer 
linkage  intervals  directly  from  WES  data  in  order  to 
restrict the search space [7].
None  of  these  analysis  strategies  is  applicable  to 
single cases of sporadic disease. The study of Vissers 
et al. [3] was motivated by recent estimations that put 
the  per  generation  mutation  rate  at  about  1  in  100 
million  positions  in  the  haploid  genome,  which 
corresponds  to  0.86  de  novo  amino  acid  altering 
mutations per newborn [8,9].
The  authors  [3]  developed  an  analysis  strategy  that 
involves  a  family-based  WES  approach  in  which  case-
parent trios are sequenced in order to identify potentially 
pathogenic de novo changes in the exome sequences of 
the  affected  children.  De  novo  copy  number  variations 
(CNVs) are a known cause of mental retardation, so array 
comparative genome hybridization (CGH) investigations 
were  used  to  rule  out  such  CNVs  before  WES  was 
performed.  The  exome  sequences  of  the  affected  child 
and  the  healthy  parent  of  ten  trios  were  captured  in 
solution, and approximately 3 Gb of mappable sequence 
data was generated for each individual, with about 90% of 
the  exons  of  the  about  18,000  targeted  genes  being 
covered at least 10 times. There were nearly 22,000 high-
confidence  variant  calls  per  individual,  which  were 
analyzed  using  a  bioinformatic  pipeline  to  exclude 
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were  unlikely  to  be  disease-causing  mutations.  The 
remain  ing  changes  were  filtered  against  databases  of 
common variants, which reduced the search space to an 
average of 143 variants per patient. These variants were 
then compared with the exome sequences of the parents 
to remove inherited variants, leaving between two and 
seven candidate de novo mutations per trio.
WES  data  are  still  relatively  noisy,  with  both  false-
positive and false-negative variant calls being relatively 
common. Therefore, the authors [3] set out to validate 
the WES results using targeted Sanger sequencing. For 
instance, in one trio with seven candidate mutations, five 
of  the  mutations  could  not  be  validated  by  Sanger 
sequencing  in  the  index  patient  (and  were  thus  false-
positive WES calls in the index patient), and one of the 
mutations was found by Sanger sequencing in one of the 
parents (a false-negative WES call in the parent). In total, 
Sanger sequencing led to the validation of nine de novo 
mutations in seven of the ten trios (Figure 1).
De novo mutations are a common cause of sporadic 
cases of mental retardation
The  de  novo  mutations  were  all  identified  in  different 
genes. A de novo nonsense mutation was identified in a 
2-year-old  boy  with  mental  retardation  in  RAB39B,  a 
gene encoding a small GTPase; this mutation is a known 
cause of X linked mental retardation (also called MRX72; 
MIM ID 300271). Another de novo nonsense mutation 
was found in an 8-year-old girl with mental retardation in 
SYNGAP1  (encoding  synaptic  Ras  GTPase  activating 
protein 1), a known cause of autosomal dominant mental 
retardation (also called MRD5; MIM ID 612621). No de 
novo mutation could be validated in the 10-year-old boy 
of trio 10, but a maternally inherited non-synonymous 
variant  in  JARID1C  (also  known  as  KDM5C,  or  lysine 
(K)-specific demethylase 5C) was identified. Mutations in 
this gene are a well known cause of syndromic X-linked 
mental  retardation  (MIM  ID  300534).  In  four  other 
individuals, de novo mutations were found in four genes 
that seem to be highly likely candidates based on model 
organism  studies  and  sequence  conservation  of  the 
affected  amino  acid  residues,  but  that  had  not  been 
previously proven to be related to mental retardation in 
humans.  Strictly  speaking,  the  proof  that  mutations  in 
these genes cause mental retardation in humans will have 
to  await  the  identification  of  additional  mutations  in 
more patients.
The  authors  [3]  identified  several  additional  de  novo 
variants in their patients that probably have nothing to 
do with the mental retardation. These changes were in 
genes with no obvious connection to mental functioning, 
occurred in less highly conserved residues, and in two 
cases were found in addition to other de novo mutations 
Figure 1. Family-based diagnostic strategy for sporadic cases of 
mental retardation [3]. After excluding de novo pathogenic copy 
number variations (CNVs) by array CGH analysis and ruling out fragile 
X syndrome, whole-exome sequencing is performed on the index 
case and the unaffected parents. A series of bioinformatic filters are 
used to narrow down the list of candidate mutations. First, mutations 
deemed to be irrelevant, such as intergenic and synonymous 
mutations, are removed; common variants are then removed by 
comparison with genetic variation databases and exome sequencing 
controls. Finally, inherited variants are removed. The average number 
of candidate variants after each step in the ten trios investigated by 
Vissers et al. [3] is shown on the right, and the number next to the 
dotted arrow indicates the fold reduction of candidates achieved by 
each step. The final analysis step is performed by means of Sanger 
sequencing to validate the candidates derived by computational 
analysis of the WES data.
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seemed unlikely that these mutations are related to the 
cases  of  mental  retardation.  This  leads  to  the  obvious 
con  clusion that the mere finding of a de novo missense 
mutation  by  WES  cannot  be  taken  as  proof  that  the 
change is causally related to the disease being investigated.
It  has  been  notoriously  difficult  to  provide  an 
etiological diagnosis in cases of sporadic mental retarda-
tion.  Although  detection  rates  vary  widely  between 
different  reports,  in  general  it  has  been  possible  to 
identify the cause of mental retardation in less than half 
of patients even after an extensive analysis [10]. Vissers et 
al.  [3]  identified  the  conclusive  or  probable  cause  of 
mental retardation in seven of the ten cases they exam-
ined. Their results suggest that de novo mutations are a 
major cause of mental retardation and that family-based 
WES is not only an excellent approach for diagnostics in 
sporadic mental retardation but also a method of choice 
for  the  discovery  of  novel  disease  genes  in  mental 
retardation.  It  is  tempting  to  speculate  that  similar 
approaches might be fruitful for other classes of sporadic 
disease with an apparent genetic background. The work 
of Vissels et al. [3] provides yet another demonstration of 
the enormous potential that the revolutionary method of 
WES  has  to  improve  diagnostic  routines  in  genetics 
clinics and beyond.
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